See Bull Run's current company pages for Cipla and Mankind Pharma. For a larger global comparison, see Bull Run's Sun Pharma vs Mankind Pharma analysis.

The gap is only about ₹26 crore.

That makes this much more useful than a simple ₹7,119 crore versus ₹4,031 crore consolidated revenue comparison.

Q1 FY27 scorecard: much more Cipla revenue, almost the same EBITDA

The domestic businesses are effectively the same size

This may be the most useful fact in the entire comparison.

Cipla is widely perceived as a substantially larger pharmaceutical company.

That is true globally.

But inside India, Mankind has already built a commercial franchise approaching Cipla's broad quarterly domestic scale.

The definitions are also reasonably comparable

Cipla's One-India reporting includes:

• branded prescription medicines;
• trade generics;
• consumer health.

Mankind's domestic reporting includes:

• domestic pharmaceutical formulations;
• BSV specialty products;
• Consumer Healthcare.

The exact accounting categories are not identical, but both capture the broad Indian operating franchise rather than only prescription medicines.

Cipla's India business grew 12%

One-India delivered the highest-ever quarterly revenue in the company's history.

Cipla's branded prescription business delivered market growth of around 15.4% according to company-cited IQVIA data.

Key therapies remained strong.

The company reported:

• 13% respiratory growth;
• 10% urology growth;
• 26% anti-diabetes growth;
• 14% cardiac growth;
• 11% dermatology growth.

Cipla's chronic mix reached 60.4%

This is important because chronic medicines are among the most valuable parts of the Indian pharmaceutical market.

Respiratory, diabetes and cardiac patients often require continuous therapy.

This creates repeat prescriptions and less volatile demand.

Cipla has particularly deep brand recognition in respiratory disease.

Mankind's domestic business grew 10.5%

Mankind generated approximately ₹3,426 crore domestic revenue.

Domestic pharmaceuticals excluding Consumer Healthcare generated ₹3,180 crore and grew 11%.

Consumer Healthcare generated ₹246 crore and grew around 4%.

Growth was driven by chronic therapies, acute recovery and BSV specialty products.

Mankind's chronic portfolio grew 15.8%

The company's chronic business is becoming increasingly important.

Cardiac sales grew approximately 19.4%.

Anti-diabetes excluding certain newer-product effects continued outgrowing the broader market.

Mankind's Glizid family grew approximately 29%, while its Telmikind family grew roughly 21%.

This is the part of Mankind's business that can most directly close the quality gap with long-established chronic players such as Cipla.

Acute therapies are recovering too

Mankind's acute portfolio growth improved from approximately 6.1% in Q1 FY26 to around 10.9% in Q1 FY27.

Gastroenterology, vitamins and minerals, and gynaecology contributed to the recovery.

This creates broader domestic growth rather than dependence entirely on cardiac and diabetes.

Cipla has the stronger respiratory moat

Respiratory remains one of Cipla's defining therapy areas.

Foracort is one of India's largest pharmaceutical brands.

Cipla's respiratory manufacturing and device expertise also extends into international markets.

This combines:

• domestic brand strength;
• inhaler engineering;
• formulation science;
• physician relationships;
• global regulatory capabilities.

Mankind does not yet possess an equivalent global respiratory franchise.

Mankind's strongest structural advantage is prescription reach

Mankind has built extraordinary physical distribution across India.

The company reports more than:

• 18,500 field-force professionals;
• 17,600 stockists;
• 500,000 doctors reached;
• leadership by prescriptions;
• one of India's largest medicine-volume franchises.

This network allows it to launch products across a massive physician base.

BSV is changing the quality of Mankind's portfolio

This matters because Mankind historically created value through volume, affordability and distribution.

BSV adds products where scientific complexity and manufacturing capability become more important.

The combination can increase both margin and revenue per doctor relationship.

BSV's women's-health franchise is particularly strategic

Mankind reported continued strong double-digit growth from the BSV specialty business in Q1.

Its gynaecology and fertility franchises include products used across fertility treatment and women's healthcare.

Mankind reported strong IVF growth in brands including Foligraf and Humog during the quarter.

These therapies have higher entry barriers than many mass-market generic tablets.

Cipla is taking a different route toward higher-value medicines

Cipla is investing in respiratory, peptides, obesity, differentiated generics and selected specialty opportunities.

Its Yurpeak obesity franchise was among the important recent Indian launches.

The company's anti-diabetes portfolio grew strongly in Q1.

This gives Cipla exposure to one of India's fastest-growing pharmaceutical categories.

Both companies therefore want more chronic and specialty revenue

The strategies differ, but the economic goal is similar.

Higher-value therapies can produce:

• better margins;
• greater prescription durability;
• higher barriers to entry;
• less dependence on commodity generics;
• stronger lifetime patient economics.

International exposure is where Cipla separates itself

India represented approximately 48% of Cipla's Q1 revenue.

The remainder came from North America, Africa, Emerging Markets, Europe, APIs and other operations.

Mankind generated approximately ₹605 crore international revenue, representing only around 15% of Q1 sales.

Cipla therefore has far more geographic diversification.

Mankind's international business is growing much faster

International revenue increased 29% to ₹605 crore.

The smaller base means international expansion can materially change Mankind's consolidated growth rate over time.

The business includes markets across the US and other international geographies, with BSV also expanding the addressable overseas portfolio.

Domestic concentration is not automatically a weakness

India's pharmaceutical market has substantial structural growth drivers:

• rising chronic disease;
• higher diagnosis rates;
• greater healthcare access;
• insurance expansion;
• urbanisation;
• higher incomes;
• increasing prescription penetration.

Mankind can therefore generate attractive growth without depending heavily on the volatile US generic market.

Cipla's global diversification creates different risks

Cipla's North America Q1 demonstrates the disadvantage of international exposure.

US revenue declined sharply as high-value products normalized and supply constraints affected certain assets.

International pharmaceutical markets create exposure to:

• FDA actions;
• generic price erosion;
• product exclusivity cycles;
• foreign exchange;
• litigation;
• customer concentration.

Domestic Indian branded medicines generally face a different risk structure.

The margin comparison is dramatic—but probably temporary

Cipla's EBITDA fell to ₹1,192 crore from ₹1,778 crore in Q1 FY26.

Mankind's EBITDA increased 24.7% to ₹1,060 crore.

The absolute difference between the companies was only ₹132 crore.

Mankind produced almost Cipla-level EBITDA on 43% less revenue

Mankind's revenue was only around 57% of Cipla's.

Its EBITDA was around 89% of Cipla's.

This demonstrates the current difference in revenue quality.

Mankind's branded domestic and specialty-heavy mix produced substantially better Q1 profit conversion.

Cipla's Q1 EBITDA should have more recovery potential

Cipla's North America mix was unusually weak.

Management continues to expect respiratory and other differentiated launches to support future US growth.

If revenue recovers while temporary costs fade, incremental North America sales can generate substantial operating leverage.

This means Cipla can potentially grow EBITDA faster than consolidated revenue during a recovery phase.

Mankind's margin expansion looks more structural

Mankind's gross margin improved to approximately 72.8%.

EBITDA margin expanded around 250 basis points.

Drivers included:

• better chronic mix;
• BSV specialty contribution;
• price and portfolio mix;
• operating leverage.

Management has guided toward maintaining a mid-20s EBITDA margin range for FY27.

The balance-sheet difference remains meaningful

Mankind's deleveraging is progressing quickly

Net debt declined to approximately ₹3,377 crore by June 30, 2026.

Net debt to adjusted EBITDA improved to around 0.9x.

This is important because the BSV acquisition initially increased financial leverage.

Each rupee of debt repayment reduces future finance cost and improves equity economics.

Cipla can deploy cash rather than repay acquisition debt

Cipla's large net-cash balance creates different capital-allocation choices.

It can invest in:

• R&D;
• licensing;
• acquisitions;
• manufacturing;
• shareholder distributions.

The challenge is earning an attractive return on that cash rather than allowing it to depress consolidated ROE indefinitely.

R&D intensity is much higher at Cipla

Cipla invested approximately ₹486 crore in R&D during Q1, equal to 6.8% of revenue.

Mankind invested around ₹98 crore, approximately 2.4% of revenue.

This reflects their different strategies.

Cipla develops a larger regulated-market and differentiated-product pipeline.

Mankind relies more heavily on domestic brands, in-licensing and acquired specialty capabilities.

Higher R&D can create long-term upside—but is not automatically better

Research spending creates value only when products reach the market and generate attractive returns.

Cipla's US and respiratory investments therefore need successful approvals and launches.

Mankind's lower internal R&D intensity can be efficient if acquisitions and licensing deliver similar commercial opportunities at better returns.

Capital returns currently slightly favour Cipla

Cipla has the higher current ROCE.

Mankind has slightly higher ROE despite greater leverage.

As Mankind repays BSV acquisition debt, investors should watch whether ROCE moves upward.

Valuation favours Cipla despite its weaker quarter

The companies' market capitalisations are surprisingly close.

Cipla is valued at approximately ₹1.16 lakh crore.

Mankind is valued at approximately ₹1.05 lakh crore.

Cipla therefore has only about 10% more market value despite generating 77% more Q1 revenue.

Why does Mankind command the higher earnings multiple?

The market is paying for:

• faster domestic growth;
• margin expansion;
• chronic portfolio growth;
• BSV specialty optionality;
• deleveraging;
• long-duration Indian healthcare growth.

Cipla's current multiple is lower partly because earnings momentum is weak and North America remains uncertain.

But Mankind's valuation leaves less room for mistakes

A 51x P/E and 6.4x price-to-book multiple require long-duration growth.

If domestic growth slows into high single digits or BSV fails to improve capital returns, valuation compression can offset earnings growth.

Mankind therefore needs execution across both operations and capital allocation.

Cipla needs earnings recovery more than multiple expansion

At roughly 34.5x trailing earnings, Cipla is not a low-P/E stock in absolute terms.

But its Q1 profit base is visibly depressed.

If EBITDA margin recovers while the P/E remains unchanged, earnings alone can improve the valuation equation.

This makes Cipla a recovery-plus-quality thesis rather than a pure growth thesis.

Historical free cash flow also favours Cipla

Bull Run's current database shows approximately ₹13,262 crore of cumulative five-year free cash flow for Cipla.

Mankind's comparable field is approximately ₹5,697 crore.

Mankind's shorter listed history and acquisition cycle affect the comparison, but Cipla's long-term cash-generation record remains a major strength.

Both stocks have weak recent momentum

Cipla is down approximately 10.3% over one year in Bull Run's latest snapshot.

Mankind is down approximately 6.5%.

This means neither current valuation is driven by a large recent momentum bubble.

The next rerating is more likely to depend on operating performance.

What must Cipla prove?

• Q1 margin weakness must reverse.
• North America needs successful differentiated launches.
• India should continue delivering double-digit growth.
• Respiratory leadership needs protection.
• Obesity and metabolic products should scale.
• R&D investment needs commercial conversion.
• Large net cash should be allocated productively.

What must Mankind prove?

• Domestic revenue should continue outgrowing the Indian market.
• Chronic growth should remain in the mid-teens or better.
• BSV needs sustained specialty growth.
• International revenue should become a larger contributor.
• Acquisition debt needs continued reduction.
• ROCE should improve as BSV matures.
• Earnings must justify a 50x-plus P/E.

What could make Cipla outperform Mankind?

A sharp recovery in North America profitability.

Cipla already has almost the same domestic business scale as Mankind.

If US revenue and margin recover while India continues growing, Cipla gains a second earnings engine without needing the Indian business to accelerate dramatically.

Its lower P/E increases the effect of that recovery.

What could make Mankind outperform Cipla?

Continued high-margin domestic compounding.

If chronic therapies grow mid-teens, BSV expands faster than the market and debt keeps declining, Mankind can compound PAT substantially faster than revenue.

The smaller international base also provides additional optionality.

Which has the stronger India business?

Almost a draw on broad quarterly revenue.

Cipla One-India generated ₹3,452 crore versus Mankind domestic revenue of ₹3,426 crore.

Cipla has stronger respiratory leadership; Mankind has greater prescription-volume reach and a growing BSV specialty platform.

Which has the stronger current EBITDA margin?

Mankind Pharma.

Q1 EBITDA margin reached 26.3% compared with Cipla at 16.7%.

Cipla's margin, however, appears unusually depressed.

Which has the stronger global diversification?

Cipla by a wide margin.

Only around 48% of Q1 revenue came from One-India, while approximately 85% of Mankind's revenue remained domestic.

Which has the stronger balance sheet?

Cipla.

It had approximately ₹9,494 crore net cash, while Mankind remains in a manageable but real post-BSV net-debt position.

Which has the stronger valuation?

Cipla.

Its trailing P/E is approximately 34.5x versus Mankind around 51.3x, while price-to-book is also substantially lower.

Which is better: Cipla or Mankind Pharma?

Cipla currently has the stronger valuation-adjusted diversified profile. Its Indian business is essentially the same quarterly size as Mankind's, but Cipla also owns significant international franchises, has nearly ₹9,500 crore net cash, generates greater historical free cash flow and trades at a materially lower P/E.

Mankind currently has the stronger near-term margin and domestic-growth profile. EBITDA margin reached 26.3%, PAT grew 29%, chronic therapies grew 15.8%, BSV is strengthening specialty exposure and acquisition leverage is falling.

The decision therefore depends on what investors believe about Cipla's current earnings weakness.

If 16.7% is temporary and North America recovers, Cipla's lower valuation is compelling.

If Cipla's US profitability remains structurally weak while Mankind continues expanding margins and chronic share, Mankind can justify part of its premium.

At September 2026 valuations, Cipla has the stronger risk-adjusted setup because it combines equivalent domestic scale with greater global diversification and a lower valuation. Mankind offers the faster domestic compounding story, but its 51x P/E requires continued margin expansion, BSV execution and improving capital returns.

Frequently asked questions